Clinical Trial Update: Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating amyloid imaging and safety of ACC-001 in subjects with early Alzheimer's disease was completed, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• ACC-001

Snippet

Sponsor: Pfizer | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED | Results posted: 2016-02-25